<?xml version='1.0' encoding='utf-8'?>
<document id="19280517"><sentence text="Drug-drug interaction studies in preclinical species: should metabolite(s) kinetics be studied?" /><sentence text="Drug-drug interaction studies are important building blocks in drug development to understand the perceived risk of a purported interaction due to the differing clinical pharmacology attributes of the co-administered drugs" /><sentence text=" Two case studies are presented that justify the importance of evaluating the metabolite kinetics data along with the parent in a preclinical model" /><sentence text=" Atorvastatin and verapamil have interesting clinical pharmacology attributes in that both agents are substrates and/or inhibitors of the dual cytochrome P450 (CYP) 3A4 and P-glycoprotein (Pgp) efflux transporter interplay"><entity charOffset="1-13" id="DDI-PubMed.19280517.s4.e0" text="Atorvastatin" /><entity charOffset="18-27" id="DDI-PubMed.19280517.s4.e1" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.19280517.s4.e0" e2="DDI-PubMed.19280517.s4.e0" /><pair ddi="false" e1="DDI-PubMed.19280517.s4.e0" e2="DDI-PubMed.19280517.s4.e1" /></sentence><sentence text=" As articulated by the two case studies, the presence of metabolite kinetic data (i" /><sentence text="e" /><sentence text=", norverapamil) provided unequivocal evidence in order to tease out the actual pathway responsible for the interaction between atorvastatin and verapamil"><entity charOffset="2-14" id="DDI-PubMed.19280517.s7.e0" text="norverapamil" /><entity charOffset="127-139" id="DDI-PubMed.19280517.s7.e1" text="atorvastatin" /><entity charOffset="144-153" id="DDI-PubMed.19280517.s7.e2" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.19280517.s7.e0" e2="DDI-PubMed.19280517.s7.e0" /><pair ddi="false" e1="DDI-PubMed.19280517.s7.e0" e2="DDI-PubMed.19280517.s7.e1" /><pair ddi="false" e1="DDI-PubMed.19280517.s7.e0" e2="DDI-PubMed.19280517.s7.e2" /><pair ddi="false" e1="DDI-PubMed.19280517.s7.e1" e2="DDI-PubMed.19280517.s7.e1" /><pair ddi="false" e1="DDI-PubMed.19280517.s7.e1" e2="DDI-PubMed.19280517.s7.e2" /></sentence><sentence text=" Therefore, consideration for metabolite kinetics, wherever feasible, appears to be prudent in defining the interaction liability between the two agents in a preclinical model" /><sentence text="" /></document>